

Sanofi Pasteur Influenza Vaccine Update

National Influenza Vaccine Summit
June 29 – July 1, 2009


The vaccine division of sanofi-sintelabo Group

Sanofi Pasteur's Pandemic Preparedness

- Sanofi Pasteur is in close contact with health authorities and stands ready to support their public health efforts
 - HHS^a placed an initial order for a vaccine against novel influenza A (H1N1) virus on May 22
 - Sanofi Pasteur received the seed virus to begin production on May 27
- The FDA^b license of a new influenza vaccine manufacturing facility will increase production capacity to approximately 150 Million doses
 - New Facility: H1N1 production
 - Existing Facility: balance of seasonal production



^a US Department of Health and Human Services
^b Food and Drug Administration


The vaccine division of sanofi-sintelabo Group



Influenza A (H1N1): Production Update

- **Large-scale production of influenza A (H1N1) began in newly licensed facility**
 - Influenza vaccine production typically takes 4-5 months
 - **Clinical trials to determine dosing and schedule**
 - Trials to include adjuvanted and un-adjuvanted vaccine
 - **In contact with FDA to determine the regulatory process**
- **Decision to implement a vaccination campaign has still not been made by the Federal Government**
 - **Ordering & distribution of monovalent vaccine is expected to be controlled by the HHS**
 - **Recommendations and educational efforts to be determined**

3

sanofi pasteur
The science of well-being



Sanofi Pasteur Production Update for 2009-2010 Fluzone[®], Influenza Virus Vaccine

- **Production of 50 Million doses remains on track for the 2009-2010 season**
 - Reservation process closes for all presentations except 0.25mL Pediatric Dose
- **Expected to ship 50% of seasonal Fluzone vaccine doses in August and be completed in October**
 - **2 US manufacturing facilities provides for earlier and increased availability of no preservative presentations**
 - **Capacity exists to significantly increase production of No Preservative Fluzone vaccine**
 - Increased production of No Preservative Fluzone Vaccine for the 2009-2010 season
 - Full conversion to no preservative presentations is contingent on provider demand

4

sanofi pasteur
The science of well-being




While the Pandemic Has Raised Concerns, Cannot Lose Focus on Seasonal Influenza

- Seasonal influenza remains a serious public health threat
 - 36,000 deaths and 226,000 hospitalizations in the US each year
 - “More kids die from influenza than all other vaccine-preventable diseases combined” – *Andrew Kroger, CDC*
 - 4 out of 5 Americans are recommended to be immunized against seasonal influenza
- Patient anxiety over influenza A (H1N1) will likely drive earlier and increased demand for seasonal vaccine
- Key challenge:
 - Need to utilize the seasonal vaccine early (August – October) due to unknown distribution, immunization process, and timing of influenza A (H1N1)



Expanded Immunization Recommendations Provide More Influenza Vaccination Opportunities

39 Million (69%) 5 through 18 year-olds had one or more visits to a primary care physician during the 2007 influenza season¹



(As of July 31, 2007 the US Census Population Estimate for the 5-18 year age group is 57,692,196)²

1. Surveillance Data, Inc. (SDI), February 2008. Ad Hoc Report on Patients Aged 5 to 18 Years, January to December 2007. Based on nationally projected data from physician office electronic medical claims submitted on CMS-1500 forms for third-party reimbursement. 2. Claritas, Inc., a division of The Nielsen Company, 2007 U.S. Population Estimates by Age.



Sanofi Pasteur's Commitment to the Future

- **Robust R&D program investigating product innovations that:**
 - Address the special medical needs of specific populations
 - Provide enhanced delivery methods
- **On the Horizon: Fluzone High-Dose (IM)**
 - High-dose trivalent, inactivated split influenza virus vaccine candidate formulated with no preservative or adjuvant
 - 0.5mL dose in a pre-filled syringe
 - Proposed indication is for active immunization against influenza disease for older adults